# Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease

> **NCT04151225** · PHASE2 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Crohns Disease
- Crohn's Disease

## Interventions

- **DRUG:** GSK2330811
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04151225
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-04-05
- **Primary completion:** 2024-04-22
- **Final completion:** 2025-05-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Internal sponsor decision to terminate project in Crohn's disease due to potential narrow therapeutic window. No subjects were enrolled
- **Last updated:** 2022-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04151225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04151225, "Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04151225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*